Piggybacking Towards Progress for CAR-T Cell Therapy in Prostate Cancer.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 42307267.
- Also identified by DOI 10.1158/1078-0432.CCR-26-0959.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
P-PSMA-101 is a first-in-class, stem cell memory T cell-enriched, PSMA-targeting CAR-T therapy. This cellular therapy showed notable clinical activity in two patients; however, PSA50 responses were generally modest. While severe immune effector-related toxicities were observed in some patients, a novel iCasp9 safety switch was largely effective in mitigating toxicity.